Montelukast sodium : administration to children to control intermittent asthma

Show simple item record Gravett, Cornelia M. Tintinger, Gregory Ronald Theron, Annette J. Anderson, Ronald Feldman, Charles Green, Robin J. 2011-06-21T07:01:24Z 2011-06-21T07:01:24Z 2010
dc.description.abstract The prototype cysteinyl leukotriene receptor antagonist, montelukast, is generally considered to have a niche application in the chemotherapy of exercise-induced asthma. It has also been used as add-on therapy in patients whose asthma is poorly controlled with inhaled corticosteroid monotherapy, or with the combination of a long-acting β(2)-agonist and an inhaled corticosteroid. Recently, however, montelukast has been reported to possess secondary anti-inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors. These novel activities enable montelukast to target eosinophils, monocytes, and, in particular, the corticosteroid-insensitive neutrophil, suggesting that this agent may have a broader spectrum of anti-inflammatory activities than originally thought. If so, montelukast is potentially useful in the chemotherapy of intermittent asthma because most exacerbations of this condition involve respiratory virus infection-triggered inflammatory mechanisms which, to a large extent, involve airway epithelial cell/neutrophil interactions. The primary objective of this review is to evaluate the role of montelukast in the treatment of intermittent asthma in children. en_US
dc.description.sponsorship RA is in receipt of research funding from MSD. CG has received payment for talks from MSD, Astra Zeneca, GlaxoSmith Kline, and Sanofi Aventis and has been sponsored for congress travel by MSD. CF and RG are advisory board members for MSD, serve on the speakers bureau for MSD and have received sponsorship for congress travel from MSD. en_US
dc.identifier.citation Gravett, CM, Tintinger, GR, Theron, AJ, Anderson, R, Feldman, C & Green, R 2010, 'Montelukast sodium : administration to children to control intermittent asthma', Clinical Medicine Reviews in Therapeutics, vol. 2, pp. 1-10. [] en_US
dc.identifier.issn 1179-2558
dc.language.iso en en_US
dc.publisher Libertas Academica en_US
dc.rights © the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited. en_US
dc.subject Airway epithelial cells en_US
dc.subject Corticosteroids en_US
dc.subject Inflammation en_US
dc.subject Neutrophils en_US
dc.subject Respiratory viruses en_US
dc.subject Virus-induced wheeze en_US
dc.subject Montelukast sodium en
dc.subject.lcsh Exercise-induced asthma -- Treatment en
dc.title Montelukast sodium : administration to children to control intermittent asthma en_US
dc.type Article en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record